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Background
The development of new therapies for heart failure
(HF) is a high priority. The endogenous natriuretic
peptides (NPs) ANP, BNP, and CNP mediate cardiac
unloading, renal enhancing, vasoprotective and RAAS
suppressing actions via activation of the receptors gua-
nylyl cyclase (GC)-A and GC-B, respectively. We engi-
neered cenderitide (also known as CD-NP) as a novel
NP that activates both GC-A and GC-B, with higher
activity at GC-B so as to be less hypotensive than the
GC-A agonists ANP and BNP. The cardiorenal and
neurohumoral actions of cenderitide in HF patients are
undefined. We hypothesized that cenderitide would
suppress RAAS via GC-A activation, would unload the
heart while maintaining blood pressure (BP) taking
advantage of GC-B activation, and would preserve glo-
merular filtration rate (GFR) secondary to both GC-A
and GC-B.
Methods
Subjects with stable, chronic HF (ejection fraction
≤40%) were enrolled in a randomized, double-blind,
placebo-controlled, proof-of-concept study. Randomi-
zation was to either placebo (n=5) or cenderitide (20
ng/kg/min; n=9; Nile Therapeutics) for 4 hours. On
the study day, patients received their usual cardiac
medications except diuretics. GFR was measured by
iothalamate. BP, aldosterone and ANP were also
assessed, the latter to assess cardiac unloading. After
equilibration, a 60’ baseline clearance (C1) was done,
followed by two 120’ clearances (C2 and C3, respec-
tively) with cenderitide or placebo, and finally a 120’
post-infusion clearance (C4). Changes from baseline
were compared between groups. p-values are cenderi-
tide vs. placebo.
Results
Cenderitide increased cGMP, the second messenger of
the NPs, in C2 and C3 (p<0.05). Cenderitide as com-
pared to placebo did not change BP or heart rate. GFR
(p=0.04) increased with cenderitide in C2. Cenderitide
decreased aldosterone in C3 (p=0.01) and tended to do
so in C2 (p=0.054). Cenderitide decreased ANP in C4,
consistent with greater cardiac unloading.
Conclusion
Cenderitide represents a novel dual activator of GC-A
and GC-B which in human HF is safe, activates cGMP,
suppresses aldosterone, unloads the heart and preserves
renal function at a non-hypotensive dose. Further * Correspondence: costello.lisa@mayo.edu
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